These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 8596594

  • 1. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P.
    N Engl J Med; 1996 Apr 11; 334(15):939-45. PubMed ID: 8596594
    [Abstract] [Full Text] [Related]

  • 2. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Locatelli F, Carbarns IR, Maschio G, Mann JF, Ponticelli C, Ritz E, Alberti D, Motolese M, Janin G, Zucchelli P.
    Kidney Int Suppl; 1997 Dec 11; 63():S63-6. PubMed ID: 9407424
    [Abstract] [Full Text] [Related]

  • 3. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 11; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 4. Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease.
    Ishimitsu T, Akashiba A, Kameda T, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H.
    Nephrology (Carlton); 2007 Jun 11; 12(3):294-8. PubMed ID: 17498126
    [Abstract] [Full Text] [Related]

  • 5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.
    N Engl J Med; 1993 Nov 11; 329(20):1456-62. PubMed ID: 8413456
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of benazepril for advanced chronic renal insufficiency.
    Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW.
    N Engl J Med; 2006 Jan 12; 354(2):131-40. PubMed ID: 16407508
    [Abstract] [Full Text] [Related]

  • 7. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
    Zhang GH, Hou FF, Zhang X, Liu QF.
    Zhonghua Nei Ke Za Zhi; 2005 Aug 12; 44(8):592-6. PubMed ID: 16194413
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of benazepril in chronic renal insufficiency.
    van Hout BA, Simeon GP, McDonnell J, Mann JF.
    Kidney Int Suppl; 1997 Dec 12; 63():S159-62. PubMed ID: 9407447
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC, Ko GT, Chan WB, Ma RC, So WY, Lo MK, Lee KF, Ozaki R, Chow CC, Cockram CS, Chan JC.
    Diabetes Obes Metab; 2006 May 12; 8(3):342-7. PubMed ID: 16634995
    [Abstract] [Full Text] [Related]

  • 10. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril.
    Bursztyn M, Gavras I, Gourley L, DeSilva J, Whalen J, Gavras H.
    Clin Ther; 1994 May 12; 16(3):429-36. PubMed ID: 7923309
    [Abstract] [Full Text] [Related]

  • 11. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
    Giri S, Mahajan SK, Sen R, Sharma A.
    J Assoc Physicians India; 2002 Oct 12; 50():1245-9. PubMed ID: 12568207
    [Abstract] [Full Text] [Related]

  • 12. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
    Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T.
    J Am Soc Nephrol; 2007 Jun 12; 18(6):1880-8. PubMed ID: 17513327
    [Abstract] [Full Text] [Related]

  • 13. Strict blood-pressure control and progression of renal failure in children.
    ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.
    N Engl J Med; 2009 Oct 22; 361(17):1639-50. PubMed ID: 19846849
    [Abstract] [Full Text] [Related]

  • 14. Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
    Li XM, Cong HL, Li TT, He LJ, Zhou YJ.
    Chin Med J (Engl); 2011 Jul 22; 124(14):2101-6. PubMed ID: 21933609
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.
    Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC.
    N Engl J Med; 1992 Apr 02; 326(14):910-5. PubMed ID: 1542341
    [Abstract] [Full Text] [Related]

  • 16. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 17. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 18. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP.
    J Am Soc Nephrol; 2007 Jun 20; 18(6):1889-98. PubMed ID: 17494885
    [Abstract] [Full Text] [Related]

  • 19. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
    Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS.
    Nephrol Dial Transplant; 2003 Oct 20; 18(10):2047-53. PubMed ID: 13679479
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.